TrialNCT07434791
Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)
- Status
- RECRUITING
- Phase
- NA
- Last update posted
- 09/04/2026
- Start
- 08/26/2026
- Sponsor
- Sunnybrook Health Sciences Centre
- Specialties
- diabetes
Conditions: Diabetic Kidney Disease (DKD); Type 2 Diabetes Mellitus (T2DM); Chronic Kidney Disease
Brief summary
GOLD-STANDARD is a pragmatic, open-label pilot randomized controlled trial evaluating the feasibility, safety, and implementation of an early goal-directed Cardio-Kidney-Metabolic (CKM) care strategy compared with usual care in adults with type 2 diabetes and diabetic kidney disease who are at increased cardiovascular risk. Participants will be followed for 12 months to assess treatment uptake, adherence, retention, and safety outcomes, and to inform the design of a future definitive trial.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.